---
title: "NK Cell Engagers: Next-Generation Immunotherapy and What Their Clinical Development Requires"
description: How NK cell engagers work, what early DF1001 data showed in HER2-expressing solid tumors, and key considerations for dose selection and indication strategy.
image: https://www.crystalbiosolutions.com/hubfs/CBS%20lab/DSCF0117-min.jpg
---

![Crystal Bio Solutions logo](https://www.crystalbiosolutions.com/hs-fs/hubfs/Crystal%20Bio%20Solutions%20logo.webp?width=330&height=150&name=Crystal%20Bio%20Solutions%20logo.webp)

- Bioanalysis & Biomarkers 
    - [All Bioanalysis & Biomarker Services](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [PK Assays for Biologics & ADCs](https://www.crystalbiosolutions.com/services/pk-bioanalysis)
    - [NAb & ADA Immunogenicity Assays](https://www.crystalbiosolutions.com/ada-and-nab-testing-in-biologics-pk-efficacy-and-regulatory-risk)
    - [Receptor Occupancy Assays](https://www.crystalbiosolutions.com/services/receptor-occupancy-assays)
- Biologics CMC Analytical 
    - [All Biologics CMC Analytical Services](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Developability Assessment](https://www.crystalbiosolutions.com/services/biologics-developability-assessment)
    - [Extended Characterization by HRMS](https://www.crystalbiosolutions.com/services/biologics-extended-characterization-hrms)
    - [Biotransformation & In Vivo CQA](https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa)
- [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
- Solutions 
    - [ADC Programs](https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc)
    - [Regulatory Affairs Support](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)

- [Resources](https://www.crystalbiosolutions.com/news-and-events)
- [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
- [About Us](https://www.crystalbiosolutions.com/about-us)
- [Locations](https://www.crystalbiosolutions.com/locations)
- [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Request a Proposal](https://www.crystalbiosolutions.com/contact-us)

Nov 22, 2026

# NK Cell Engagers: Next-Generation Immunotherapy and What Their Clinical Development Requires

How NK cell engagers work, what early DF1001 data showed in HER2-expressing solid tumors, and key considerations for dose selection and indication strategy.

![NK Cell Engagers: Next-Generation Immunotherapy and What Their Clinical Development Requires](https://www.crystalbiosolutions.com/hubfs/CBS%20lab/DSCF0117-min.jpg)\\

Natural killer (NK) cells are a key part of the immune system. They kill target cells through several cytotoxic mechanisms and shape immune responses through cytokines, which has made them a focus of cancer immunotherapy. Many NK-directed strategies are now in development, including antibody-based and cell-based NK therapies and combinations that drive NK responses \[1\]. NK cell engagers (NKCEs) are among the most promising.

## The NK cell engager approach

NK-cell-mediated cancer immunotherapy has advanced quickly over the past two decades. Multispecific NK cell engagers have recently been developed that direct endogenous NK cells to lyse tumor cells carrying a specific antigen. Their structures vary, but they generally combine a tumor-antigen binding domain with domains that bind NK activating receptors, such as CD16, NKp30, NKp46, and NKG2D. Many show strong antitumor activity in early studies.

## DF1001: a HER2-targeted tri-specific NK cell engager

At ASCO 2023, Dragonfly Therapeutics reported early data for DF1001, a potential first-in-class tri-specific NK cell engager therapy (TriNKET) for advanced solid tumors \[2\]. DF1001 targets HER2 and is designed to activate both innate and adaptive immunity in solid tumors. It received FDA orphan drug designation for esophageal cancer in 2021. The data below are as reported at that meeting.

### Study design

The first-in-human Phase 1/2 study evaluated the safety, tolerability, and early biological and clinical activity of DF1001. Preclinical data showed that TriNKETs stimulate NK cells, γδ T cells, and CD8+ T cells directly and indirectly. As of December 8, 2022, the dose-escalation phase had enrolled 36 patients with advanced or refractory solid tumors, starting at a very low 0.000052 mg/kg and escalating to 15 mg/kg. The expansion phase enrolled 68 patients with solid tumors expressing at least HER2 1+, at 0.52–15 mg/kg every two weeks, and also explored combinations with nivolumab or nab-paclitaxel. Biopsies taken before treatment and after 4–6 weeks showed a trend toward more CD8+ T-cell and NK-cell infiltration in tumors, supporting proof of concept.

### Results

DF1001 showed antitumor activity in heavily pretreated patients (up to 16 prior lines), including patients previously treated with trastuzumab deruxtecan (Enhertu, T-DXd), across metastatic breast cancer (MBC), colorectal cancer, non-small cell lung cancer (NSCLC), and gastroesophageal cancer. In MBC patients who had received an average of six prior lines (most HER2-low), 25% achieved a clinical response. Data were too limited to relate HER2 expression level to response.

Treatment-related adverse events (TRAEs) were reported in 79% of patients. Most were low grade (86% grade 1–2) and rarely led to discontinuation. No grade 4 or 5 TRAEs and no dose-limiting toxicities were reported. The most common TRAEs were infusion-related reactions (26%), asthenia (15%), and fatigue (12%). At the time, a Phase 2 study in HER2-expressing solid tumors had dosed its first patient (December 6, 2022), and combinations with Gilead's Trop-2 ADC Trodelvy were planned in MBC and NSCLC.

## Why HER2-targeted NK cell engagers could fill a gap

The DF1001 results suggest HER2-targeted NK cell engagers could address unmet needs in tumors that express HER2 without gene amplification. Common HER2 alterations include mutation, amplification, and protein overexpression \[3\]. In most tumor types, amplification and overexpression are highly correlated \[4\]. Most clinically validated anti-HER2 therapies target tumors with both, leaving few options for HER2-low tumors.

Data from My Cancer Genome show that HER2 amplification is most common in breast, gastroesophageal, lung, and colorectal cancers. Data from The Human Protein Atlas show HER2 protein expression across many more solid tumors, which could benefit from anti-HER2 therapy.

For HER2 mutations, the link between mutation and overexpression differs by tumor type, and existing anti-HER2 therapies vary in efficacy across mutated tumors \[5\]. Because mutation and overexpression are thought to drive tumors through different mechanisms, therapies for HER2-mutant tumors are also an urgent need. Approved anti-HER2 therapies remain concentrated in breast and gastroesophageal cancer. Trastuzumab deruxtecan is approved for HER2-low breast cancer, and approved HER2-directed options in lung cancer are limited to HER2-mutant disease. The main gaps are therefore in other HER2-positive, HER2-low, or HER2-mutant tumors.

## Considerations for clinical development of NK cell engagers

A sound overall development plan and regulatory path should reflect the drug's characteristics, including the potential for single-arm accelerated approval and orphan or breakthrough designations.

FDA's Project Optimus has raised expectations for dose finding, selection, and optimization in oncology:

- **Starting dose.** For first-in-class agents, agents with high or unknown risk, agents without a relevant toxicology species, and agonists that can trigger amplifying cascades, several approaches, including the minimal anticipated biological effect level (MABEL), are usually needed to justify the starting dose.
- **Dose exploration.** Expect more subjects and longer toxicity observation periods.
- **Dose optimization.** After escalation and initial expansion, identify several candidate doses or ranges and compare them in randomized studies.
- **Combinations.** For drugs intended for combination use, early studies should generate enough dose-selection evidence to support later combination trials.

Tumor types and indications should be chosen based on the drug's properties, mechanism, preclinical results, and the sponsor's strategy. An NK cell engager can be thought of as an amplifier for a given tumor-target drug. Common tumors with low target expression, and rare tumors with high target expression or poor response to current therapy, are promising directions.

Developing a novel immunotherapy? Learn about our [regulatory affairs](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt) and [clinical pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology) support, or [contact us](https://www.crystalbiosolutions.com/contact-us).

## References

1. Vivier E, et al. Natural killer cell therapies. Nature. 2024;626(8000):727–736.
2. Safran H, et al. Phase 1/2 study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results. J Clin Oncol. 2023;41(16\_suppl):2508.
3. Vranić S, Bešlija S, Gatalica Z. Targeting HER2 expression in cancer: new drugs and new indications. Bosn J Basic Med Sci. 2021;21(1):1–4.
4. Yan M, et al. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015;34(1):157–164.
5. Connell CM, Doherty GJ. Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open. 2017;2(5):e000279.

![Crystal Bio Solutions logo (footer)](https://www.crystalbiosolutions.com/hubfs/Logo_CBS-%E7%AB%96%E7%89%88-%E5%8F%8D%E7%99%BD.png)

- [Our Services](https://www.crystalbiosolutions.com) 
    - [Bioanalysis & Biomarkers](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [Biologics CMC Analytical](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
    - [Regulatory Affairs](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)
- [Information](https://www.crystalbiosolutions.com/news-and-events) 
    - [About Us](https://www.crystalbiosolutions.com/about-us)
    - [Quality & Compliance](https://www.crystalbiosolutions.com/quality-and-compliance)
    - [News & Events](https://www.crystalbiosolutions.com/news-and-events)
    - [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
    - [Scientific Articles](https://www.crystalbiosolutions.com/news-and-events/tag/blog)
    - [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Contact](https://www.crystalbiosolutions.com/contact-us) 
    - [Email Us](mailto:cbs_bd@crystalpharmatech.com)
    - [Contact Form](https://www.crystalbiosolutions.com/contact-us)
    - [Our Locations](https://www.crystalbiosolutions.com/locations)
    - [Crystal Group](https://www.crystalbiosolutions.com/about-us#crystal-group) 
          - [Crystal Pharmatech](https://www.crystalpharmatech.com/)
          - [Crystal NAX](https://www.crystalnax.com/)

<https://www.linkedin.com/company/crystal-bio-solutions/> [Follow us on LinkedIn News, events and openings](https://www.linkedin.com/company/crystal-bio-solutions/)

- [Privacy Policy](https://www.crystalbiosolutions.com/policies/privacy-policy)
- [Terms of Service](https://www.crystalbiosolutions.com/policies/terms-of-service)

Copyright © 2026 Crystal Bio Solutions, Inc. All rights reserved.

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "CBS Marketing Team",
    "url" : "https://www.crystalbiosolutions.com/news-and-events/author/cbs-marketing-team"
  },
  "dateModified" : "2026-11-22T17:58:49.605Z",
  "datePublished" : "2026-11-22T17:58:49.000Z",
  "headline" : "NK Cell Engagers: Next-Generation Immunotherapy and What Their Clinical Development Requires",
  "image" : [ "https://www.crystalbiosolutions.com/hubfs/CBS%20lab/DSCF0117-min.jpg" ],
  "mainEntityOfPage" : {
    "@id" : "https://www.crystalbiosolutions.com/news-and-events/nk-cell-engagers-next-generation-immunotherapy-and-what-their-clinical-development-requires",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://www.crystalbiosolutions.com/hubfs/Crystal%20Bio%20Solutions%20logo.webp"
    },
    "name" : "Crystal Bio Solutions"
  }
}
```